Overview of NRG1 Fusions

Opinion
Video

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.

Educational support for this activity provided by Merus.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Russ Conroy
August 15th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
August 15th 2025
Podcast
Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
August 15th 2025
Article
1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
August 15th 2025
Podcast
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.

FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer

Tim Cortese
August 15th 2025
Article
Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

ONCOLOGY Staff
August 15th 2025
Article